Scholarlink

Background <p>The study aimed to investigate the role of fibrinogen, the fibrinogen/albumin ratio (FAR), and the creatinine/fibrinogen ratio (CFR) in predicting Placental Abruption (PA) and composite adverse perinatal outcomes (CAPO).</p> Methods <p>This retrospective case–control study was performed at a tertiary center between September 2022 and February 2024. Pregnant women diagnosed with PA and healthy controls, matched for maternal age were included. Fibrinogen, FAR, and CFR values and their relationship with PA were assessed. The PA group was further divided based on the presence or absence of CAPO. The utility of these biomarkers in predicting PA and CAPO was analyzed.</p> Results <p>A total of 180 women (90 PA, 90 controls) were included. Fibrinogen and FAR levels were significantly lower in the PA group than in the control group (p &lt; 0.001, for both). However CFR values were significantly higher (0.129 vs. 0.096, p &lt; 0.001). Among PA patients, CFR was significantly higher in those with CAPO (0.138 vs. 0.113, p &lt; 0.001), but fibrinogen and FAR were significantly lower (p &lt; 0.001 and p = 0.031). CFR predicted PA with an AUC of 0.890 and predicted CAPO within the PA group with an AUC of 0.767. In multivariable analysis, CFR was independently associated with both PA (aOR = 2.81, p &lt; 0.001) and the CAPO within the PA group (aOR = 1.37, p = 0.008).</p> Conclusion <p>CFR could be a valuable and cost-effective biomarker for early diagnosis and risk stratification in PA. Incorporating CFR into clinical practice could improve the timely detection of high-risk cases and guide appropriate treatment strategies to reduce maternal and neonatal complications.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Assessing the Role of Creatinine to Fibrinogen Ratio and Fibrinogen to Albumin Ratio in Predicting Placental Abruption and Perinatal Outcomes: A Case–Control Study

  • 期刊论文

  • 发表日期：

    2025年9月11日

查看全文
  • Recep Taha Ağaoğlu,
  • Seval Yılmaz Ergani,
  • Dilara Sarıkaya Kurt,
  • Burak Hizli,
  • Özge Öztürk,
  • Aziz Kindan,
  • Özgür Volkan Akbulut,
  • Eyüp Gökhan Turmuş,
  • Zeynep Şeyhanli,
  • Kadriye Yakut Yücel

摘要

Background

The study aimed to investigate the role of fibrinogen, the fibrinogen/albumin ratio (FAR), and the creatinine/fibrinogen ratio (CFR) in predicting Placental Abruption (PA) and composite adverse perinatal outcomes (CAPO).

Methods

This retrospective case–control study was performed at a tertiary center between September 2022 and February 2024. Pregnant women diagnosed with PA and healthy controls, matched for maternal age were included. Fibrinogen, FAR, and CFR values and their relationship with PA were assessed. The PA group was further divided based on the presence or absence of CAPO. The utility of these biomarkers in predicting PA and CAPO was analyzed.

Results

A total of 180 women (90 PA, 90 controls) were included. Fibrinogen and FAR levels were significantly lower in the PA group than in the control group (p < 0.001, for both). However CFR values were significantly higher (0.129 vs. 0.096, p < 0.001). Among PA patients, CFR was significantly higher in those with CAPO (0.138 vs. 0.113, p < 0.001), but fibrinogen and FAR were significantly lower (p < 0.001 and p = 0.031). CFR predicted PA with an AUC of 0.890 and predicted CAPO within the PA group with an AUC of 0.767. In multivariable analysis, CFR was independently associated with both PA (aOR = 2.81, p < 0.001) and the CAPO within the PA group (aOR = 1.37, p = 0.008).

Conclusion

CFR could be a valuable and cost-effective biomarker for early diagnosis and risk stratification in PA. Incorporating CFR into clinical practice could improve the timely detection of high-risk cases and guide appropriate treatment strategies to reduce maternal and neonatal complications.